Similar Items: Strategies for optimising TB-HIV co-treatment in children and adolescents with drug-susceptible tuberculosis on rifampicin-based standard regimens
- Population pharmacokinetic modelling to optimise treatment for children with Rifampicin-resistant TB and HIV
- Does the inclusion of the cost and burden of adverse drug reactions associated with drug-resistant TB treatment affect the incremental cost-effectiveness of new treatment regimens? A case study from the introduction of bedaquiline in South Africa National TB Programme
- And therapeutic outcomes lopinavir-ritonavir and a rifampicin containing anti-tuberculosis pharmacokinetics in children with tuberculosis/hiv co-infection treated with regimen
- Nonlinear mixed-effects modelling of drug-drug interactions between antiretroviral therapy and tuberculosis treatment
- The prevalence of isoniazid and rifampicin resistance of Mycobacterium tuberculosis
- Diagnostic outcomes of CT-guided lung biopsy in an HIV and TB co-infection prevalent region